RPRD1A

Summary

RPRD1A (regulation of nuclear pre-mRNA domain containing 1A, HGNC:25560) is a protein-coding gene on chromosome 18q12.2, encoding Regulation of nuclear pre-mRNA domain-containing protein 1A (Q96P16). Interacts with phosphorylated C-terminal heptapeptide repeat domain (CTD) of the largest RNA polymerase II subunit POLR2A, and participates in dephosphorylation of the CTD by RPAP2.

This gene encodes a cell-cycle and transcription regulatory protein. The encoded protein interacts with the cell cycle inhibitor cyclin-dependent kinase 4 inhibitor B and may function as a negative regulator of G(1)/S phase progression. This protein also forms homo- and hetrodimers with the protein, regulation of nuclear pre-mRNA domain-containing protein 1B, to form a scaffold that interacts with the C-terminal domain of RNA polymerase II subunit B1 and regulates several aspects of transcription. Alternate splicing results in multiple transcript variants. A pseudogene of this gene is found on chromosome 16.

Source: NCBI Gene 55197 — RefSeq curated summary.

At a glance

• GWAS associations: 3
• Clinical variants (ClinVar): 32 total
• MANE Select transcript: NM_018170

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:25560
Approved symbol	RPRD1A
Name	regulation of nuclear pre-mRNA domain containing 1A
Location	18q12.2
Locus type	gene with protein product
Status	Approved
Aliases	P15RS, FLJ10656, HsT3101
Ensembl gene	ENSG00000141425
Ensembl biotype	protein_coding
OMIM	610347
Entrez	55197

Gene structure

Transcript identifiers

Ensembl transcripts: 14 — 8 protein_coding, 3 nonsense_mediated_decay, 1 protein_coding_CDS_not_defined, 1 non_stop_decay, 1 retained_intron

ENST00000357384, ENST00000399022, ENST00000585879, ENST00000585953, ENST00000587563, ENST00000588459, ENST00000588737, ENST00000589050, ENST00000590898, ENST00000591994, ENST00000592674, ENST00000896647, ENST00000916733, ENST00000966876

RefSeq mRNA: 4 — MANE Select: NM_018170 NM_001303411, NM_001303412, NM_001303413, NM_018170

CCDS: CCDS11917, CCDS77178

Canonical transcript exons

ENST00000399022 — 7 exons

Exon	Start	End
ENSE00000948469	36033708	36033837
ENSE00000948470	36030991	36031097
ENSE00000948471	36030808	36030905
ENSE00000948472	36027184	36027310
ENSE00000948473	36026900	36027075
ENSE00001536029	35989824	35993300
ENSE00003841425	36067254	36067559

Expression profiles

Bgee: expression breadth ubiquitous, 282 present calls, max score 98.39.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 41.0382 / max 703.3271, expressed in 1816 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
171671	39.5505	1816
171670	1.4878	931

Top tissues by expression

288 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
Brodmann (1909) area 23	UBERON:0013554	98.39	gold quality
endothelial cell	CL:0000115	98.24	gold quality
adrenal tissue	UBERON:0018303	97.35	gold quality
middle temporal gyrus	UBERON:0002771	96.58	gold quality
primary visual cortex	UBERON:0002436	96.36	gold quality
secondary oocyte	CL:0000655	96.07	gold quality
corpus epididymis	UBERON:0004359	95.93	gold quality
ventricular zone	UBERON:0003053	95.50	gold quality
corpus callosum	UBERON:0002336	95.33	gold quality
calcaneal tendon	UBERON:0003701	95.25	gold quality
entorhinal cortex	UBERON:0002728	95.23	gold quality
occipital lobe	UBERON:0002021	95.22	gold quality
superior frontal gyrus	UBERON:0002661	95.17	gold quality
germinal epithelium of ovary	UBERON:0001304	95.12	gold quality
lateral nuclear group of thalamus	UBERON:0002736	95.05	gold quality
cortical plate	UBERON:0005343	94.96	gold quality
gingival epithelium	UBERON:0001949	94.93	gold quality
postcentral gyrus	UBERON:0002581	94.92	gold quality
ganglionic eminence	UBERON:0004023	94.89	gold quality
parietal lobe	UBERON:0001872	94.88	gold quality
prefrontal cortex	UBERON:0000451	94.86	gold quality
substantia nigra pars compacta	UBERON:0001965	94.71	gold quality
substantia nigra pars reticulata	UBERON:0001966	94.61	gold quality
temporal lobe	UBERON:0001871	94.48	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	94.38	gold quality
neocortex	UBERON:0001950	94.32	gold quality
frontal cortex	UBERON:0001870	94.26	gold quality
cerebral cortex	UBERON:0000956	94.23	gold quality
anterior cingulate cortex	UBERON:0009835	94.19	gold quality
visceral pleura	UBERON:0002401	94.11	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-HCAD-38	yes	801.75
E-ANND-3	yes	8.17
E-MTAB-7303	no	410.37

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

176 targeting RPRD1A, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-6873-3P	100.00	71.42	2626
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-3120-5P	100.00	65.56	965
HSA-MIR-30A-5P	100.00	76.31	3233
HSA-MIR-30B-5P	100.00	76.29	3248
HSA-MIR-30C-5P	100.00	76.29	3248
HSA-MIR-30D-5P	100.00	76.32	3233
HSA-MIR-30E-5P	100.00	76.32	3242
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-MIR-126-5P	100.00	72.71	3180
HSA-MIR-200B-3P	100.00	73.31	2693
HSA-MIR-200C-3P	100.00	73.35	2685
HSA-MIR-429	100.00	73.44	2698
HSA-MIR-4768-5P	100.00	69.49	2861
HSA-MIR-3064-3P	100.00	70.09	1254
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-4531	99.99	69.70	3181
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-3185	99.99	68.12	1959
HSA-MIR-12121	99.99	66.64	255
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-4775	99.98	75.00	6394

Literature-anchored findings (GeneRIF, showing 7)

• molecular cloning and characterization of P15RS, a novel P15(INK4b) related gene involved in G1/S progression (PMID:12470661)
• p15RS inhibits Wnt signaling by interrupting beta-catenin.TCF4 complex formation and that Wnt signaling initiates downstream gene expression by removing p15RS from promoters. (PMID:20739273)
• The p15RS expression specifically downregulates the expression of cathepsin B and MMP-9 at RNA levels, which are known to promote cell invasion through degrading extracellular matrix proteins. (PMID:22580456)
• RPRD1A and RPRD1B associate directly with RPAP2 phosphatase and coordinate the dephosphorylation of RNAPII phospho-S5 by RPAP2. (PMID:24997600)
• Data suggest that p15RS (p15INK4b-related sequence) acts as an intrinsic transcriptional repressor for Wnt/beta-catenin-mediated gene transcription through recruiting HDAC2 histone deacetylase. (PMID:25697359)
• The Wnt/beta-catenin signaling antagonist RPRD1A was downregulated and its upstream regulator miR-454-3p was amplified and overexpressed in metastatic breast cancer, and both were correlated with overall and relapse-free survival in breast cancer patients. (PMID:30809286)
• RPRD1A stabilizes NRF2 and aggravates HCC progression through competing with p62 for TRIM21 binding. (PMID:34921137)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	rprd1a	ENSDARG00000104861
mus_musculus	Rprd1a	ENSMUSG00000040446
rattus_norvegicus	Rprd1a	ENSRNOG00000016036
drosophila_melanogaster	CG9018	FBGN0035318
caenorhabditis_elegans		WBGENE00015347

Paralogs (2): RPRD1B (ENSG00000101413), RPRD2 (ENSG00000163125)

Protein

Protein identifiers

Regulation of nuclear pre-mRNA domain-containing protein 1A — Q96P16 (reviewed: Q96P16)

Alternative names: Cyclin-dependent kinase inhibitor 2B-related protein, p15INK4B-related protein

All UniProt accessions (5): A0A0C4DGQ6, Q96P16, K7EP82, K7EQR8, K7ER50

UniProt curated annotations — full annotation on UniProt →

Function. Interacts with phosphorylated C-terminal heptapeptide repeat domain (CTD) of the largest RNA polymerase II subunit POLR2A, and participates in dephosphorylation of the CTD by RPAP2. May act as a negative regulator of cyclin-D1 (CCND1) and cyclin-E (CCNE1) in the cell cycle.

Subunit / interactions. May form a heterodimer with RPRD1B. Associates with the RNA polymerase II subunit POLR2A (via CTD phosphorylated at ‘Ser-2’ and ‘Ser-7’ of the heptad repeats).

Subcellular location. Nucleus.

Induction. Up-regulated in cells overexpressing CDKN2B.

Similarity. Belongs to the UPF0400 (RTT103) family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q96P16-1	1	yes
Q96P16-3	2

RefSeq proteins (4): NP_001290340, NP_001290341, NP_001290342, NP_060640* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR006569	CID_dom	Domain
IPR008942	ENTH_VHS	Homologous_superfamily
IPR032337	RPRD1A/B_C	Domain
IPR047884	RPRD1A_CID	Domain

Pfam: PF04818, PF16566

UniProt features (25 total): helix 9, modified residue 4, mutagenesis site 3, sequence conflict 2, initiator methionine 1, chain 1, domain 1, turn 1, coiled-coil region 1, splice variant 1, sequence variant 1

Structure

Experimental structures (PDB)

2 structures.

PDB	Method	Resolution (Å)
4JXT	X-RAY DIFFRACTION	1.9
4NAC	X-RAY DIFFRACTION	2

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q96P16-F1	83.65	0.56

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (4): 2, 153, 156, 285

Mutagenesis-validated functional residues (3):

Position	Phenotype
65	partial loss of binding to polr2a ctd in vitro.
106	partial loss of binding to polr2a ctd phosphorylated at ‘ser-2’ in the heptad repeats in vitro.
114	partial loss of binding to polr2a ctd in vitro.

Function

Pathways and Gene Ontology

Reactome pathways

3 pathways

ID	Pathway
R-HSA-6807505	RNA polymerase II transcribes snRNA genes
R-HSA-73857	RNA Polymerase II Transcription
R-HSA-74160	Gene expression (Transcription)

MSigDB gene sets: 211 (showing top): ATF_B, RODRIGUES_THYROID_CARCINOMA_POORLY_DIFFERENTIATED_UP, CREBP1_Q2, GGGTGGRR_PAX4_03, YY1_Q6, CREB_Q4, chr18q12, GOBP_MRNA_3_END_PROCESSING, E4F1_Q6, ATF3_Q6, CREB_Q2_01, DODD_NASOPHARYNGEAL_CARCINOMA_UP, ATF_01, DEURIG_T_CELL_PROLYMPHOCYTIC_LEUKEMIA_UP, CREBP1CJUN_01

GO Biological Process (3): RNA polymerase II promoter clearance (GO:0001111), mRNA 3’-end processing (GO:0031124), regulation of transcription by RNA polymerase II (GO:0006357)

GO Molecular Function (5): RNA polymerase II complex binding (GO:0000993), identical protein binding (GO:0042802), RNA polymerase II C-terminal domain binding (GO:0099122), protein binding (GO:0005515), RNA polymerase II CTD heptapeptide repeat phosphatase activity (GO:0008420)

GO Cellular Component (3): nucleus (GO:0005634), nucleoplasm (GO:0005654), transcription preinitiation complex (GO:0097550)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
RNA Polymerase II Transcription	1
Gene expression (Transcription)	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
transcription by RNA polymerase II	2
promoter clearance during DNA-templated transcription	1
mRNA processing	1
RNA 3’-end processing	1
regulation of DNA-templated transcription	1
RNA polymerase core enzyme binding	1
protein binding	1
RNA polymerase II complex binding	1
binding	1
protein serine/threonine phosphatase activity	1
RNA polymerase II CTD heptapeptide repeat modifying activity	1
intracellular membrane-bounded organelle	1
nuclear lumen	1
cellular anatomical structure	1
protein-DNA complex	1

Protein interactions and networks

STRING

1392 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
RPRD1A	RPAP2	Q8IXW5	897
RPRD1A	RMP24	Q32NC0	662
RPRD1A	CDKN2B	P42772	642
RPRD1A	POLR2A	P24928	592
RPRD1A	PCF11	O94913	582
RPRD1A	RECQL5	O94762	571
RPRD1A	CCNE1	P24864	549
RPRD1A	CDKN3	Q16667	549
RPRD1A	SCAF8	Q9UPN6	542
RPRD1A	RPAP3	Q9H6T3	495
RPRD1A	GPN1	Q9HCN4	494
RPRD1A	SCAF4	O95104	479
RPRD1A	CCND1	P24385	477
RPRD1A	XRN2	Q9H0D6	477
RPRD1A	JAG2	Q9Y219	466

IntAct

119 interactions, top by confidence:

A	B	Type	Score
RPRD1B	POLR2A	psi-mi:“MI:0914”(association)	0.920
POLR2G	POLR2D	psi-mi:“MI:0914”(association)	0.840
POLR2J	POLR1C	psi-mi:“MI:0914”(association)	0.830
RPRD1B	RPRD1A	psi-mi:“MI:0915”(physical association)	0.820
RFXANK	RFXAP	psi-mi:“MI:0914”(association)	0.780
POLR2G	RECQL5	psi-mi:“MI:0914”(association)	0.730
RPRD1B	RECQL5	psi-mi:“MI:0914”(association)	0.730
POLR2D	MED19	psi-mi:“MI:0914”(association)	0.730
POLR2E	MED19	psi-mi:“MI:0914”(association)	0.730
RPRD1B	POLR2D	psi-mi:“MI:0914”(association)	0.730
POLR2J	POLR2D	psi-mi:“MI:0914”(association)	0.730
CFTR	ESYT2	psi-mi:“MI:2364”(proximity)	0.710
POLR2A	RPAP2	psi-mi:“MI:0914”(association)	0.640
POLR2D	RECQL5	psi-mi:“MI:0914”(association)	0.640
POLR2L	RCCD1	psi-mi:“MI:0914”(association)	0.640
POLR2F	POLR3A	psi-mi:“MI:0914”(association)	0.640
POLR2L	POLR3A	psi-mi:“MI:0914”(association)	0.640
POLR2A	RPRD1A	psi-mi:“MI:0915”(physical association)	0.620
RPRD1A	KPNA3	psi-mi:“MI:0915”(physical association)	0.560
KPNA3	RPRD1A	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (211): RPRD1A (Two-hybrid), RPRD1A (Affinity Capture-RNA), RPRD1A (Affinity Capture-RNA), RPRD1A (Affinity Capture-MS), RPRD1A (Affinity Capture-MS), RPRD1A (Affinity Capture-MS), RPRD1A (Affinity Capture-MS), RPRD1A (Affinity Capture-MS), RPRD1A (Affinity Capture-MS), DPH2 (Co-fractionation), DXO (Co-fractionation), MITD1 (Co-fractionation), RPRD1A (Co-fractionation), RPRD1A (Co-fractionation), VPS37B (Co-fractionation)

ESM2 similar proteins: A0JMA8, A4UUI3, A8WLG6, A8WZU5, A8XEZ1, A8XY47, F4ICD9, F4JIN3, G5EDN3, O13745, O43150, O59668, O74737, O74749, O93436, P32744, P34281, P38753, P90740, Q03609, Q07872, Q0P5J9, Q10410, Q17423, Q20977, Q21444, Q23088, Q4VBT2, Q5R8Y3, Q5SPP5, Q5U245, Q61D31, Q61J98, Q61QN4, Q641A2, Q756C5, Q7SIG6, Q7XPJ0, Q8IGJ0, Q8STE5

Diamond homologs: Q0P5J9, Q5R8Y3, Q5ZM30, Q8VDS4, Q96P16, Q9CSU0, Q9NQG5, Q05543, Q5VT52, Q6NXI6

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 123 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
FGFR2 mutant receptor activation	8	72.5×	2e-12
Signaling by FGFR2 IIIa TM	9	64.4×	1e-12
Abortive elongation of HIV-1 transcript in the absence of Tat	9	53.2×	2e-12
MicroRNA (miRNA) biogenesis	9	48.9×	4e-12
Activation of HOX genes during differentiation	9	47.1×	5e-12
FGFR2 alternative splicing	9	45.3×	7e-12
RNA Polymerase III Chain Elongation	6	45.3×	2e-08
Pausing and recovery of Tat-mediated HIV elongation	10	43.9×	1e-12

GO biological processes:

GO term	Partners	Fold	FDR
transcription by RNA polymerase II	10	6.1×	2e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

32 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	22
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1885 predictions. Top by Δscore:

Variant	Effect	Δscore
18:36026895:CGCA:C	donor_gain	1.0000
18:36026896:GCA:G	donor_loss	1.0000
18:36026897:CACTT:C	donor_loss	1.0000
18:36026898:A:AC	donor_gain	1.0000
18:36026898:ACTT:A	donor_gain	1.0000
18:36026898:ACTTC:A	donor_gain	1.0000
18:36026899:C:CA	donor_gain	1.0000
18:36026899:CTT:C	donor_gain	1.0000
18:36026899:CTTC:C	donor_gain	1.0000
18:36026899:CTTCC:C	donor_gain	1.0000
18:36026901:T:TA	donor_gain	1.0000
18:36026902:C:A	donor_gain	1.0000
18:36026931:T:TA	donor_gain	1.0000
18:36027076:C:CC	acceptor_gain	1.0000
18:36027076:C:CG	acceptor_loss	1.0000
18:36027178:TCTTA:T	donor_loss	1.0000
18:36027179:CTTA:C	donor_loss	1.0000
18:36027180:TTA:T	donor_loss	1.0000
18:36027181:TA:T	donor_loss	1.0000
18:36027182:A:AG	donor_loss	1.0000
18:36027183:C:CT	donor_loss	1.0000
18:36027309:GT:G	acceptor_gain	1.0000
18:36027310:TCT:T	acceptor_loss	1.0000
18:36030637:C:CT	donor_gain	1.0000
18:36030638:T:TT	donor_gain	1.0000
18:36030802:TTCTA:T	donor_loss	1.0000
18:36030803:TCTA:T	donor_loss	1.0000
18:36030804:CTA:C	donor_loss	1.0000
18:36030805:TA:T	donor_loss	1.0000
18:36030807:C:T	donor_loss	1.0000

AlphaMissense

2039 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
18:36031005:A:G	L125P	1.000
18:36031032:A:T	V116D	1.000
18:36031037:C:A	R114S	1.000
18:36031037:C:G	R114S	1.000
18:36031038:C:A	R114M	1.000
18:36031038:C:G	R114T	1.000
18:36031046:C:A	W111C	1.000
18:36031046:C:G	W111C	1.000
18:36031047:C:G	W111S	1.000
18:36031048:A:G	W111R	1.000
18:36031048:A:T	W111R	1.000
18:36031050:A:C	I110S	1.000
18:36031050:A:G	I110T	1.000
18:36031050:A:T	I110N	1.000
18:36031061:T:A	R106S	1.000
18:36031061:T:G	R106S	1.000
18:36031062:C:G	R106T	1.000
18:36033746:A:C	F81L	1.000
18:36033746:A:T	F81L	1.000
18:36033747:A:G	F81S	1.000
18:36033748:A:G	F81L	1.000
18:36033758:A:C	F77L	1.000
18:36033758:A:T	F77L	1.000
18:36033759:A:C	F77C	1.000
18:36033759:A:G	F77S	1.000
18:36033760:A:G	F77L	1.000
18:36033768:C:T	G74E	1.000
18:36033769:C:G	G74R	1.000
18:36033769:C:T	G74R	1.000
18:36033776:C:A	K71N	1.000

dbSNP variants (sampled 300 via entrez): RS1000005328 (18:36042740 A>C), RS1000017776 (18:36059264 A>C,G), RS1000054492 (18:36064508 A>G), RS1000191925 (18:36063317 G>A), RS1000323673 (18:35992964 TAAGTC>T), RS1000334916 (18:36036945 C>T), RS1000365667 (18:36067754 C>A), RS1000379695 (18:36044125 A>G), RS1000426987 (18:35999154 C>T), RS1000451826 (18:36064291 T>A,G), RS1000473815 (18:36023941 T>C), RS1000479200 (18:36025542 C>A,G,T), RS1000491014 (18:36026067 C>A,T), RS1000504190 (18:36003653 T>C), RS1000561443 (18:36017108 G>A)

Disease associations

OMIM: gene MIM:610347 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

3 associations (top):

Study	Trait	p-value
GCST002269_1	Drug-induced torsades de pointes	4.000000e-07
GCST90002390_550	Mean corpuscular hemoglobin	1.000000e-11
GCST90002392_29	Mean corpuscular volume	1.000000e-11

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0004527	mean corpuscular hemoglobin

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

40 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	increases expression, affects cotreatment, decreases expression, affects expression	7
bisphenol A	decreases expression, affects cotreatment, affects expression, increases abundance	2
sodium arsenite	affects expression, decreases expression	2
Phenylmercuric Acetate	affects cotreatment, decreases expression	2
FR900359	increases phosphorylation	1
ginger extract	affects cotreatment, affects expression, increases abundance	1
dicrotophos	decreases expression	1
methylmercuric chloride	decreases expression	1
triphenyl phosphate	affects expression	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
ochratoxin A	increases expression	1
coumarin	increases phosphorylation	1
beta-methylcholine	affects expression	1
di-n-butylphosphoric acid	affects expression	1
2,3,5-(triglutathion-S-yl)hydroquinone	increases ADP-ribosylation	1
chloropicrin	decreases expression	1
entinostat	decreases expression	1
monomethylarsonous acid	decreases expression	1
K 7174	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	decreases expression, affects cotreatment	1
dorsomorphin	affects cotreatment, decreases expression	1
jinfukang	decreases expression	1
Sunitinib	increases expression	1
Vorinostat	increases expression	1
Benzo(a)pyrene	increases mutagenesis	1
Doxorubicin	decreases expression	1
Enzyme Inhibitors	decreases activity, increases O-linked glycosylation	1
Ethyl Methanesulfonate	decreases expression	1
Formaldehyde	decreases expression	1
Ivermectin	decreases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.